Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 May;4(2):260-6.
doi: 10.1159/000328802. Epub 2011 May 24.

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy

Satoshi Takeuchi  1 , Rio Honma, Jun Taguchi, Toraji Amano, Yasushi Shimizu, Ichiro Kinoshita, Kanako Kubota, Yoshihiro Matsuno, Hirotoshi Dosaka-Akita
Affiliations
Case Reports

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy

Satoshi Takeuchi et al. Case Rep Oncol. 2011 May.

Abstract

High-grade neuroendocrine carcinoma differs from usual neuroendocrine carcinoma, and its prognosis is dismal. In this case report, a case of high-grade neuroendocrine carcinoma that improved with bevacizumab plus modified FOLFOX6 as the fourth-line chemotherapy is presented. A 29-year-old male with a huge liver tumor was diagnosed with high-grade neuroendocrine carcinoma originating from the liver. Multiple liver and bone metastases were found one month after surgery. He was treated with three chemotherapy regimens used for the management of small-cell lung cancer with extensive disease. However, none of them could be maintained because of tumor progression. He was then treated with bevacizumab plus modified FOLFOX6 as the fourth-line regimen. Dramatic tumor shrinkage was obtained, and a partial response was achieved. This case suggests that high-grade neuroendocrine carcinoma can be treated with bevacizumab in combination with cytotoxic chemotherapy.

Keywords: Bevacizumab; High-grade neuroendocrine carcinoma; Liver origin; Small-cell lung cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CT scan at the first visit. A huge tumor (over 10 cm) is seen in the right liver lobe, along with liver metastasis and lymph node swelling. b 18F-FDG-PET scan at the first visit. No distant metastases were detected. The primary lesion was thought to be in the liver.
Fig. 2
Fig. 2
Histopathological examination reveals high-grade neuroendocrine carcinoma. a Hematoxylin and eosin staining shows tumor cells are characterized by a solid and trabecular architecture. The forming of rosettes are seen (arrowheads). Tumor cells have nuclear pleomorphism and granular cytoplasm. b Chromogranin A immunostaining is seen in almost all carcinoma cells. c The MIB-1 index is about 70% in the lesion with the highest value. d TTF-1 immunostaining is negative.
Fig. 3
Fig. 3
a, b CT scan prior to chemotherapy with bevacizumab plus mFOLFOX6. Three cytotoxic regimens for small-cell lung cancer with extensive-stage disease have been given by this point. c, d CT scan after four cycles of bevacizumab plus mFOLFOX6. Liver metastases are markedly smaller compared with those before the treatment with this regimen.
See this image and copyright information in PMC

References

    1. NCCN Practice Guidelines in Oncology: Neuroendocrine Tumor. NCCN Practice Guidelines in Oncology, Version 2, 2010.
    1. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799–800. - PMC - PubMed
    1. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–1355. - PMC - PubMed
    1. Cho CS, Labow DM, Tang L, et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer. 2008;113:126–134. - PubMed
    1. NCCN Practice Guidelines in Oncology: Small Cell Lung Cancer. NCCN Clinical Guidelines in Oncology, Version 1, 2011.

Publication types